Skip to main content

23-03-2021 | Rheumatology | News | Article

News in brief

Lupus ‘may impact’ COVID-19 prognosis

Author: Claire Barnard

medwireNews: A French nationwide study has described COVID-19 outcomes in patients with systemic lupus erythematosus (SLE).

Arthur Mageau (Hôpital Bichat-Claude Bernard, Paris) used a healthcare database to evaluate the outcomes of all 1411 people with SLE and COVID-19 who were hospitalized in France between March and October 2020.

They found that overall mortality rates were significantly decreased among people with SLE and COVID-19 compared with the general population hospitalized with COVID-19 during the same period, at 9.5% versus 15.7%. However, they note that mortality rates in younger people (<70 years) “tended to be higher” among those with SLE relative to the general population, albeit without reaching statistical significance.

“Because lupus activity and the need for immunosuppressive drugs decline with age, the higher mortality rate observed in younger patients […] suggests that SLE disease may impact COVID-19 outcome,” write the researchers in a letter to the Annals of the Rheumatic Diseases.

In accordance with previous studies, Mageau and team also found that older age, male sex, and comorbidities, including chronic kidney disease and hypertension, were risk factors for poor COVID-19 outcomes in people with SLE.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

23 March 2021: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Ann Rheum Dis 2021; doi:10.1136/annrheumdis-2021-220010

See the research in context now

with trial summaries, expert opinion and congress coverage